3D Medicines Inc.

SEHK:1244 Stock Report

Market Cap: HK$816.0m

3D Medicines Management

Management criteria checks 2/4

3D Medicines' CEO is John Gong, appointed in Jan 2018, has a tenure of 6.92 years. total yearly compensation is CN¥287.61M, comprised of 0.6% salary and 99.4% bonuses, including company stock and options. directly owns 14.79% of the company’s shares, worth HK$120.68M. The average tenure of the management team and the board of directors is 4.3 years and 3.5 years respectively.

Key information

John Gong

Chief executive officer

CN¥287.6m

Total compensation

CEO salary percentage0.6%
CEO tenure6.9yrs
CEO ownership14.8%
Management average tenure4.3yrs
Board average tenure3.5yrs

Recent management updates

Recent updates

Benign Growth For 3D Medicines Inc. (HKG:1244) Underpins Stock's 26% Plummet

Aug 20
Benign Growth For 3D Medicines Inc. (HKG:1244) Underpins Stock's 26% Plummet

3D Medicines Inc. (HKG:1244) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough

Jul 05
3D Medicines Inc. (HKG:1244) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough

3D Medicines Inc. (HKG:1244) Stock Catapults 43% Though Its Price And Business Still Lag The Industry

May 21
3D Medicines Inc. (HKG:1244) Stock Catapults 43% Though Its Price And Business Still Lag The Industry

CEO Compensation Analysis

How has John Gong's remuneration changed compared to 3D Medicines's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-CN¥450m

Mar 31 2024n/an/a

-CN¥487m

Dec 31 2023CN¥288mCN¥2m

-CN¥525m

Sep 30 2023n/an/a

-CN¥710m

Jun 30 2023n/an/a

-CN¥894m

Mar 31 2023n/an/a

-CN¥959m

Dec 31 2022CN¥104mCN¥2m

-CN¥1b

Dec 31 2021CN¥80mCN¥2m

-CN¥1b

Compensation vs Market: John's total compensation ($USD39.42M) is above average for companies of similar size in the Hong Kong market ($USD231.13K).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.

CEO

John Gong (59 yo)

6.9yrs

Tenure

CN¥287,613,000

Compensation

Dr. Zhaolong Gong, also known as John, Ph D., M.D. serves as Consultant at Ocean Pine Healthcare Fund. Previously, he served as Chief Executive Officer of JOINN Suzhou, Vice President and Managing Director...

Leadership Team

NamePositionTenureCompensationOwnership
Zhaolong Gong
Key Founder6.9yrsCN¥287.61m14.79%
HK$ 120.7m
Jing Zhang
Chief Financial Officer4.3yrsno datano data
Shen Xiao
Chief Strategy Officer & Chief Medical Officer3.8yrsno datano data
Fang Xia
Head of Regulatory Affairs4.3yrsno datano data
Ching Yi Li
Joint Company Secretary3.5yrsno datano data

4.3yrs

Average Tenure

54yo

Average Age

Experienced Management: 1244's management team is considered experienced (4.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Zhaolong Gong
Key Founder5.2yrsCN¥287.61m14.79%
HK$ 120.7m
Feng Zhou
Non-Executive Director5.2yrsno data0.012%
HK$ 99.9k
Tat Pang Lin
Independent Non-Executive Director3.5yrsCN¥315.00kno data
Li Jin
Independent Non-Executive Director3.5yrsCN¥315.00kno data
Pai Zhu
Non-Executive Director3.5yrsno data0.017%
HK$ 136.5k
Xinguang Liu
Independent Non-Executive Director3.5yrsCN¥315.00kno data
Yawen Chen
Non-Executive Director2.4yrsno datano data

3.5yrs

Average Tenure

58yo

Average Age

Experienced Board: 1244's board of directors are considered experienced (3.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 06:38
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

3D Medicines Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution